Moderate Evidence
Research Overview
Oveporexton Research for Narcolepsy Type 1
An overview of research and source records on Oveporexton in the context of narcolepsy type 1.
Research Summary
Oveporexton is specifically developed for NT1, caused by autoimmune destruction of orexin-producing neurons. The Phase 2 trial TAK-861-2001 (NCT05687903, NEJM 2025) demonstrated significant improvements in MWT sleep latency (primary), ESS, and weekly cataplexy rate; Phase 3 trials (NCT06470828, NCT06505031) are completed with results pending publication. FDA Breakthrough Therapy designation.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.